

# Heiner Wedemeyer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8572569/heiner-wedemeyer-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

579  
papers

28,099  
citations

79  
h-index

150  
g-index

694  
ext. papers

33,711  
ext. citations

6.1  
avg, IF

6.99  
L-index

#	Paper	IF	Citations
579	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 161-176	18.8	1196
578	Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2584-93	27.4	1089
577	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 461-511	13.4	1079
576	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1973-82	59.2	754
575	Treatment of acute hepatitis C with interferon alfa-2b. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1452-57	37.2	634
574	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. <i>Journal of Immunology</i> , <b>2002</b> , 169, 3447-58	5.3	540
573	Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. <i>Cancer Research</i> , <b>2005</b> , 65, 2457-64	10.1	500
572	Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1604-14	59.2	488
571	Treating viral hepatitis C: efficacy, side effects, and complications. <i>Gut</i> , <b>2006</b> , 55, 1350-9	19.2	474
570	Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 677-84	8	459
569	Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. <i>Hepatology</i> , <b>2009</b> , 50, 799-807	11.2	433
568	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 545-551	13.4	407
567	Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 5692-7	11.5	365
566	Hepatitis delta virus. <i>Lancet, The</i> , <b>2011</b> , 378, 73-85	40	351
565	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 514-22	13.4	311
564	Peginterferon plus adefovir versus either drug alone for hepatitis delta. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 322-31	59.2	303
563	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , <b>2004</b> , 127, 1347-55	13.3	284

562	Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 354-369	59.2	281
561	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , <b>2010</b> , 51, 73-80	11.2	275
560	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 34-59	3.4	271
559	Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2010</b> , 7, 31-40	24.2	264
558	EASL Clinical Practice Guidelines on hepatitis E virus infection. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1256-1271	13.4	246
557	Hepatitis E virus infection. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17086	51.1	244
556	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1121-31	13.4	237
555	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1170-1218	13.4	237
554	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , <b>2008</b> , 47, 1856-62	11.2	226
553	Pathogenesis and treatment of hepatitis e virus infection. <i>Gastroenterology</i> , <b>2012</b> , 142, 1388-1397.e1	13.3	223
552	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 490-8	13.4	222
551	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , <b>2011</b> , 54, 1947-55	11.2	207
550	Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. <i>Journal of Virology</i> , <b>2001</b> , 75, 11392-400	6.6	199
549	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. <i>Hepatology</i> , <b>2006</b> , 43, 250-6	11.2	195
548	Expert opinion on the treatment of patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 75-90	3.4	192
547	Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. <i>Liver International</i> , <b>2009</b> , 29, 1500-6	7.9	180
546	Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. <i>Journal of Immunology</i> , <b>2015</b> , 194, 2467-71	5.3	176
545	Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. <i>Hepatology</i> , <b>2010</b> , 52, 1611-20	11.2	164

544	Natural history of acute and chronic hepatitis C. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2012</b> , 26, 401-12	2.5	160
543	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , <b>2014</b> , 60, 87-97	11.2	159
542	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. <i>Hepatology</i> , <b>2005</b> , 41, 832-5	11.2	158
541	Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. <i>Gastroenterology</i> , <b>2010</b> , 138, 1885-97	13.3	154
540	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , <b>2010</b> , 16, 74-82	4.5	149
539	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , <b>2015</b> , 64, 1289-95	19.2	146
538	Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. <i>Hepatology</i> , <b>2011</b> , 54, 60-9	11.2	146
537	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , <b>2016</b> , 65, 1861-1870	19.2	146
536	Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 256-63	3.4	144
535	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 60-89	3.4	140
534	A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. <i>Gastroenterology</i> , <b>2014</b> , 147, 1008-11.e7; quiz e15-6	13.3	137
533	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , <b>2013</b> , 62, 760-5	19.2	132
532	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , <b>2011</b> , 54, 443-51	11.2	132
531	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , <b>2012</b> , 55, 695-708	11.2	126
530	Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. <i>Liver International</i> , <b>2013</b> , 33, 722-6	7.9	126
529	Chronic hepatitis e in heart transplant recipients. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 3128-338.7		120
528	Hepatitis D virus infection--not a vanishing disease in Europe!. <i>Hepatology</i> , <b>2007</b> , 45, 1331-2; author reply 1332-3	11.2	112
527	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 520-6	13.4	107

526	Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 1273-85	13.4	107
525	Telomerase gene mutations are associated with cirrhosis formation. <i>Hepatology</i> , <b>2011</b> , 53, 1608-17	11.2	107
524	Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 491-7	3.3	104
523	Cytotoxic CD4 T cells in viral hepatitis. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 505-14	3.4	102
522	Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , <b>2016</b> , 46, 2204-10	6.1	102
521	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , <b>2016</b> , 65, 1733-43	39.2	101
520	The impact of hepatitis E in the liver transplant setting. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1418-29	13.4	99
519	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 493-500	13.4	96
518	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , <b>2009</b> , 50, 1638-45	11.2	96
517	Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 1483-92	5.8	96
516	Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002045	7.6	94
515	High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. <i>Journal of Medical Virology</i> , <b>2004</b> , 73, 387-91	19.7	89
514	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 606-617	25.5	89
513	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 792-800	13.4	88
512	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 539-557	13.4	88
511	Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 366-75	13.4	87
510	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 3275-82	5.6	86
509	Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 889-901	6.1	84

508	Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. <i>Journal of Virology</i> , <b>2013</b> , 87, 6172-81	6.6	82
507	Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. <i>PLoS ONE</i> , <b>2013</b> , 8, e55285	3.7	82
506	The role of zinc in liver cirrhosis. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 7-16	3.1	82
505	Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 512-21	3.4	81
504	Compromised function of natural killer cells in acute and chronic viral hepatitis. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1362-73	7	80
503	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 1092-8	2.4	80
502	Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1965-1974	7	79
501	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , <b>2017</b> , 17, 215-222	25.5	78
500	Hepatitis C new drugs. <i>Journal of the International AIDS Society</i> , <b>2010</b> , 13, O29-O29	5.4	78
499	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1492-1497	7	78
498	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , <b>2002</b> , 4, 23-30	5	77
497	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 606.e1-10	9.5	75
496	The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 688-94	13.4	75
495	Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. <i>Journal of Clinical Virology</i> , <b>2009</b> , 46, 210-5	14.5	74
494	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 497-506	25.5	73
493	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 561-7	11.6	72
492	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , <b>2021</b> , 138, 350-353	2.2	69
491	Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1927-8	27.4	68

490	Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S3	13.4	67
489	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , <b>2011</b> , 50, 292-6	14.5	67
488	Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 915-24	1.6	67
487	Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , <b>2010</b> , 30, 430-7	7.9	66
486	Virological and clinical characteristics of delta hepatitis in Central Europe. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 883-94	3.4	66
485	Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 2022-9	9.7	64
484	Hepatitis C virus mutation affects proteasomal epitope processing. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 250-9	15.9	64
483	Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 291-301	13.4	63
482	Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , <b>2004</b> , 40, 98-107	17.2	62
481	HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. <i>Lancet Infectious Diseases</i> , <b>2014</b> , 14, 678-679	25.5	61
480	Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 339-45	6.9	61
479	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 2132-9	5.9	58
478	Treatment options for hepatitis delta virus infection. <i>Current Infectious Disease Reports</i> , <b>2013</b> , 15, 31-8	3.9	58
477	Hepatitis E in Germany--an under-reported infectious disease. <i>Deutsches Arzteblatt International</i> , <b>2014</b> , 111, 577-83	2.5	58
476	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 275-286	25.5	57
475	Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 179-85	4.3	56
474	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 584-593	13.4	55
473	Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice. <i>PLoS ONE</i> , <b>2010</b> , 5, e13137	3.7	55



472	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 473-82	13.4	55
471	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 41-7	13.4	54
470	Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 115-22	13.4	54
469	Managing HBV in patients with impaired immunity. <i>Gut</i> , <b>2010</b> , 59, 1430-45	19.2	54
468	Long-term outcome of chronic hepatitis B in heart transplant recipients. <i>Transplantation</i> , <b>1998</b> , 66, 1347-53	5.8	54
467	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , <b>2017</b> , 65, 414-425	11.2	52
466	Proteoglycans act as cellular hepatitis delta virus attachment receptors. <i>PLoS ONE</i> , <b>2013</b> , 8, e58340	3.7	51
465	Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. <i>Gut</i> , <b>2001</b> , 48, 378-83	19.2	50
464	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , <b>2016</b> , 81, 82-9	14.5	50
463	Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 537-46	3.4	49
462	Increased HEV seroprevalence in patients with autoimmune hepatitis. <i>PLoS ONE</i> , <b>2014</b> , 9, e85330	3.7	49
461	Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2007</b> , 45, 1281-328	1.6	49
460	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , <b>2018</b> , 9, 2275	17.4	48
459	Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. <i>Addiction</i> , <b>2018</b> , 113, 868-882	4.6	46
458	Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. <i>Liver International</i> , <b>2018</b> , 38, 50-58	7.9	46
457	Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 1487-90	2.4	46
456	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1821-1830.e6	6.9	46
455	Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25 Suppl 1, 6-17	3.4	45



454	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , <b>2014</b> , 34, 1452-63	7.9	45
453	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 31-40	13.4	44
452	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 38-44	13.4	44
451	Hepatitis delta: immunopathogenesis and clinical challenges. <i>Digestive Diseases</i> , <b>2010</b> , 28, 133-8	3.2	44
450	Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 770-8	13.4	44
449	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 554-563	13.4	43
448	Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 317-9; author reply 319	11.6	43
447	Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 312-20	5.9	43
446	A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 547-554	1.6	43
445	Prevalence of HBV genotypes in Central and Eastern Europe. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 1707-17	11.7	42
444	Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. <i>Transplant International</i> , <b>2006</b> , 19, 828-33	3	42
443	Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 516-525	6.1	42
442	Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 211-217	1.6	42
441	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , <b>2018</b> , 38, 842-850	7.9	41
440	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2342-49.e1-2	6.9	41
439	Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). <i>European Journal of Radiology</i> , <b>2013</b> , 82, 1207-12	4.7	40
438	Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. <i>Journal of Immunological Methods</i> , <b>2002</b> , 271, 125-35	2.5	40
437	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1008-1015	13.4	40

436	Effects of HDV infection and pegylated interferon $\beta$ treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , <b>2015</b> , 64, 469-82	19.2	39
435	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , <b>2015</b> , 62, 1013-23	11.2	39
434	Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. <i>Journal of Virology</i> , <b>2011</b> , 85, 7613-21	6.6	39
433	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. <i>Transplant Infectious Disease</i> , <b>2016</b> , 18, 326-32	2.7	38
432	Immunopathogenesis of hepatitis E virus infection. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 71-8	7.3	38
431	PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , <b>2013</b> , 58, 524-37	11.2	38
430	Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 627-9	13.4	38
429	Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. <i>Human Molecular Genetics</i> , <b>2007</b> , 16, 1335-42	5.6	38
428	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir-dasabuvir-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 936-943	3.4	37
427	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , <b>2015</b> , 214, 29-32	2.6	37
426	Hepatitis E Virus Mutations: Functional and Clinical Relevance. <i>EBioMedicine</i> , <b>2016</b> , 11, 31-42	8.8	37
425	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , <b>2014</b> , 63, 1150-8	19.2	37
424	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 1-8	3.4	37
423	Interferon $\beta$ -stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 1351-62	7	37
422	Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 361-8	7	37
421	Human CCR4 <sup>+</sup> CCR6 <sup>+</sup> Th17 cells suppress autologous CD8 <sup>+</sup> T cell responses. <i>Journal of Immunology</i> , <b>2012</b> , 188, 6055-62	5.3	36
420	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1204-1211	11.6	36
419	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon- $\beta$ -induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 710.e1-9	9.5	35

4 <sup>18</sup>	Development and evaluation of a baseline-event-anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, e154-63	3.4	35
4 <sup>17</sup>	Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country?. <i>Transplant Infectious Disease</i> , <b>2012</b> , 14, 103-6	2.7	35
4 <sup>16</sup>	Hepatitis E in HIV-positive patients in a low-endemic country. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 598-9	3.4	35
4 <sup>15</sup>	Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 860-5	5.1	35
4 <sup>14</sup>	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <i>Hepatology</i> , <b>2006</b> , 43, 1311-6	11.2	35
4 <sup>13</sup>	Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 999-1007	13.4	35
4 <sup>12</sup>	Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 840-849	3.4	34
4 <sup>11</sup>	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 301-312	13.4	34
4 <sup>10</sup>	Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. <i>Transplant Infectious Disease</i> , <b>2014</b> , 16, 333-9	2.7	34
4 <sup>09</sup>	HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. <i>Liver International</i> , <b>2012</b> , 32, 1415-25	7.9	34
4 <sup>08</sup>	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. <i>Liver International</i> , <b>2011</b> , 31, 1395-405	7.9	34
4 <sup>07</sup>	Influenza virus infection as precipitating event of acute-on-chronic liver failure. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 797-799	13.4	34
4 <sup>06</sup>	Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 663-671	13.4	34
4 <sup>05</sup>	Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. <i>Liver International</i> , <b>2018</b> , 38, 1951-1964	7.9	33
4 <sup>04</sup>	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1168-76	4	33
4 <sup>03</sup>	Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e43143	3.7	33
4 <sup>02</sup>	Hepatitis D revival. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 140-4	7.9	32
4 <sup>01</sup>	Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. <i>Vaccine Journal</i> , <b>2011</b> , 18, 1943-50		32

400	Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189255	3.7	32
399	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 856-864	18.8	32
398	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1656-1666	7	31
397	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 889-899	13.4	31
396	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 621	8.4	31
395	High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1063-1069	13.4	31
394	Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. <i>Virology Journal</i> , <b>2007</b> , 4, 58	6.1	31
393	Anti-HDV IgM as a marker of disease activity in hepatitis delta. <i>PLoS ONE</i> , <b>2014</b> , 9, e101002	3.7	31
392	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 191-6	13.4	30
391	The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1365-72	6.1	30
390	Treatment of HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 919-28	4	30
389	Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. <i>Endoscopy</i> , <b>2012</b> , 44, 48-52	3.4	30
388	Chronic hepatitis E in liver transplant recipients: a significant clinical problem?. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2010</b> , 56, 121-8	1.6	30
387	Results of single-center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin. <i>Pediatric Transplantation</i> , <b>2013</b> , 17, 343-7	1.8	29
386	Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. <i>Hepatology</i> , <b>2012</b> , 56, 2398-403	11.2	29
385	Prevalence of hepatitis C in a German prison for young men in relation to country of birth. <i>Epidemiology and Infection</i> , <b>2007</b> , 135, 274-80	4.3	29
384	Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , <b>2020</b> , 16, 388-399	4.4	29
383	Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 539-546	2.2	28

382	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , <b>2015</b> , 89, 8304-17	6.6	28
381	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , <b>2015</b> , 64, 322-31	19.2	28
380	Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C*03:04 and modulate NK cell function. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 252-8	13.4	28
379	Enrichment of regulatory T cells in acutely rejected human liver allografts. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 3425-36	8.7	28
378	HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. <i>Journal of Clinical Virology</i> , <b>2012</b> , 53, 110-5	14.5	28
377	Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 355-60	7	28
376	Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. <i>European Journal of Clinical Investigation</i> , <b>2007</b> , 37, 54-64	4.6	28
375	Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. <i>Journal of Virology</i> , <b>2001</b> , 75, 12121-7	6.6	28
374	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , <b>2020</b> , 40, 1841-1852	7.9	28
373	Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 541-550	3.4	27
372	Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. <i>Journal of Clinical Virology</i> , <b>2007</b> , 39, 308-11	14.5	27
371	Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health. <i>Pathogens</i> , <b>2020</b> , 9,	4.5	27
370	Hepatitis E virus replication and interferon responses in human placental cells. <i>Hepatology Communications</i> , <b>2018</b> , 2, 173-187	6	26
369	HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 620-8	6.1	26
368	Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 85-92	6.1	26
367	Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. <i>Gastroenterology</i> , <b>2014</b> , 147, 119-131.e3	13.3	26
366	Hepatitis E virus infection in a hematopoietic stem cell donor. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 159-60	4.4	26
365	Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 1195-201	19.7	26

364	Clearance of chronic HCV infection during acute delta hepatitis. <i>Infection</i> , <b>2009</b> , 37, 159-62	5.8	25
363	High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. <i>PLoS ONE</i> , <b>2013</b> , 8, e78094	3.7	25
362	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , <b>2017</b> , 245, 14-18	2.6	24
361	The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2009</b> , 47, 531-40	1.6	24
360	Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , <b>2009</b> , 342, 33-48	2.5	24
359	Longer survival of liver transplant recipients with hepatitis virus coinfections. <i>Clinical Transplantation</i> , <b>2007</b> , 21, 258-64	3.8	24
358	How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 146-52	2.2	24
357	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , <b>2019</b> , 156, 1820-1833	13.3	23
356	Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. <i>Current Opinion in Virology</i> , <b>2016</b> , 20, 112-118	7.5	23
355	Hepatitis E virus infection: multiple faces of an underestimated problem. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 1045-6	13.4	23
354	Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , <b>2017</b> , 37, 196-204	7.9	23
353	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , <b>2019</b> , 71, 1070	11.2	23
352	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1053-1063	13.4	23
351	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1112-1121	13.4	22
350	Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 333-8	5.3	22
349	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1480-1484	7	22
348	Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. <i>Hepatology</i> , <b>2017</b> , 66, 1794-1804	11.2	22
347	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 270	8.4	22



346	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. <i>Antiviral Research</i> , <b>2011</b> , 92, 90-5	10.8	22
345	Hepatitis E: an emerging infectious disease in Germany?. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2011</b> , 49, 1255-6	7	22
344	Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , <b>2019</b> , 11,	6.2	21
343	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , <b>2020</b> , 72, 1177-1190	11.2	21
342	Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. <i>Hepatology</i> , <b>2014</b> , 60, 1112-3	11.2	21
341	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 260-6	13.4	21
340	Hepatitis delta and HIV infection. <i>Seminars in Liver Disease</i> , <b>2012</b> , 32, 120-9	7.3	21
339	New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. <i>Gut</i> , <b>2012</b> , 61, 1647-52	19.2	21
338	Acute CMV-Colitis in a Patient with a History of Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2003</b> , 38, 119-122	2.4	21
337	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 939-945	2.2	20
336	Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 976-83	13.4	20
335	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1334-1339	13.4	20
334	Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 744-50	3.4	20
333	High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 1090-7	2.2	20
332	The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5B2 mutation. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1201-6	13.4	20
331	Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- $\beta$ 2a treatment. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 305-12	1.6	20
330	Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 2079-88	19.7	20
329	Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 1019-20; author reply 1020-1	13.4	20



328	Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. <i>Transplantation</i> , <b>2006</b> , 81, 808-9	1.8	20
327	Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. <i>Transplantation</i> , <b>1999</b> , 68, 1503-11	1.8	20
326	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1228-1234	11.6	19
325	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 769-79	3.4	19
324	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 139-149	7	19
323	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 525	8.4	19
322	High-resolution determination of human immune cell signatures from fine-needle liver aspirates. <i>European Journal of Immunology</i> , <b>2015</b> , 45, 2154-7	6.1	19
321	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , <b>2015</b> , 35, 1845-52	7.9	19
320	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 836-45	2.2	19
319	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, 562-70	3.4	19
318	Evaluation of sound speed for detection of liver fibrosis: prospective comparison with transient dynamic elastography and histology. <i>Journal of Ultrasound in Medicine</i> , <b>2010</b> , 29, 1581-8	2.9	19
317	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 200-11	3.4	19
316	Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. <i>Hepatology</i> , <b>2020</b> , 72, 829-844	11.2	19
315	Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 305-15	3.4	19
314	Towards interferon-free treatment for all HCV genotypes. <i>Lancet, The</i> , <b>2015</b> , 385, 2443-5	40	18
313	Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13146	2.7	18
312	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 568-77	3.4	18
311	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 482-91	13.4	18

310	GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 1933-40	19.7	18
309	Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. <i>Clinical Microbiology and Infection</i> , <b>2004</b> , 10, 70-2	9.5	18
308	Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2005</b> , 43, 11-6	1.6	18
307	Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2001</b> , 36, 426-31	2.4	18
306	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S52-S53	13.4	18
305	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> ,	18.8	18
304	Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 2351-2358	4	17
303	Medication adherence among patients with chronic diseases: a survey-based study in pharmacies. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2019</b> , 112, 505-512	2.7	17
302	Evaluation of the COBAS( ) AmpliPrep/COBAS( ) TaqMan( ) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. <i>Journal of Clinical Virology</i> , <b>2015</b> , 67, 67-72	14.5	17
301	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. <i>Molecular Immunology</i> , <b>2015</b> , 63, 320-7	4.3	17
300	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
299	Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , <b>2016</b> , 16, 41-48	7.5	17
298	Human T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 510	8.4	17
297	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 982-984	13.4	17
296	Interferon-β for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1029-37	1.6	17
295	Steroid treatment for severe acute cryptogenic hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2007</b> , 45, 15-9	1.6	17
294	Effects of cyclosporine on human dendritic cell subsets. <i>Transplantation Proceedings</i> , <b>2005</b> , 37, 20-4	1.1	17
293	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23, 560-8	1	17

292	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , <b>2019</b> , 8, 41-65.1		17
291	Devil hepatitis D: an orphan disease or largely underdiagnosed?. <i>Gut</i> , <b>2019</b> , 68, 381-382	19.2	17
290	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- $\alpha$ 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 303-316	1.6	17
289	Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S103	13.4	16
288	HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 177-83	1.6	16
287	Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study. <i>HIV Medicine</i> , <b>2014</b> , 15, 245-50	2.7	16
286	Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 734-41	3.4	16
285	SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. <i>Oncotarget</i> , <b>2017</b> , 8, 17127-17139	3.3	16
284	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , <b>2018</b> , 8, 17452	4.9	16
283	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 1131-1139	9.7	15
282	Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 1586-94	5.8	15
281	Successful treatment of fulminant hepatitis B during pregnancy. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2009</b> , 47, 667-70	1.6	15
280	PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. <i>PLoS ONE</i> , <b>2014</b> , 9, e94512	3.7	15
279	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. <i>Visceral Medicine</i> , <b>2015</b> , 31, 290-6	2.4	14
278	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , <b>2015</b> , 35, 2358-62	7.9	14
277	Membranous Budd-Chiari syndrome in Caucasians. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 226-34	2.4	14
276	Adenosine and IFN- $\alpha$ synergistically increase IFN-gamma production of human NK cells. <i>Journal of Leukocyte Biology</i> , <b>2009</b> , 85, 452-61	6.5	14
275	Angiopoietin-2 in acute liver failure. <i>Critical Care Medicine</i> , <b>2012</b> , 40, 1499-505	1.4	14

274	Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1049-58	1.6	14
273	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1359-1368	3.4	14
272	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1188-1198	5.3	14
271	Automated low-flow ascites pump in a real-world setting: complications and outcomes. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 1082-1089	2.2	14
270	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 696-699	13.4	13
269	Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. <i>PLoS ONE</i> , <b>2014</b> , 9, e108751	3.7	13
268	Development of a protocol for the quantitative determination of HBeAg using the Elecsys <sup>®</sup> HBeAg immunoassay. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e179-83	3.4	13
267	Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2010</b> , 48, 258-63	1.6	13
266	The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 51, 356-7	11.2	13
265	Spontaneous clearance of chronic hepatitis C after liver transplantation: are hepatitis C virus-specific T cell responses the clue?. <i>Liver Transplantation</i> , <b>2008</b> , 14, 1225-7	4.5	13
264	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110857	3.7	13
263	Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. <i>AIDS Reviews</i> , <b>2019</b> , 21, 126-134	5	13
262	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 431-440	13.4	13
261	Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , <b>2021</b> , 117, 102591	15.5	13
260	Safety and performance of liver biopsies in liver transplant recipients. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 585-9	3.8	12
259	Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. <i>Viral Immunology</i> , <b>2012</b> , 25, 442-7	1.7	12
258	Polyethylene glycol-interferon: current status in hepatitis C virus therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2002</b> , 17 Suppl 3, S344-50	4	12
257	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 12-19	3.4	12

256	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, 848-856	1.6	11
255	Chronic Hepatitis E is associated with cholangitis. <i>Liver International</i> , <b>2019</b> , 39, 1876-1883	7.9	11
254	Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. <i>Liver International</i> , <b>2018</b> , 38, 1906-1910	7.9	11
253	Estimating HCV disease burden - volume 3 (editorial). <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22 Suppl 4, 1-3	3.4	11
252	Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays. <i>Intervirology</i> , <b>2015</b> , 58, 283-7	2.5	11
251	Natural history: the importance of viral load, liver damage and HCC. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2008</b> , 22, 1063-79	2.5	11
250	Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175304	3.7	11
249	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 673-684	13.4	10
248	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , <b>2018</b> , 35, 843-857	4.7	10
247	Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1384-1394	3.4	10
246	In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity. <i>PLoS ONE</i> , <b>2014</b> , 9, e105375	3.7	10
245	Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. <i>Hepatology</i> , <b>2009</b> , 49, 1449-59	11.2	10
244	Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 2648-56	4.3	10
243	Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1243-1244	13.4	10
242	Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 196-204	3.4	10
241	Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 117-123	1.6	10
240	Treatment of chronic hepatitis B. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2010</b> , 56, 451-65	1.6	10
239	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e2-e3	13.4	9

238	The adverse effects of interferon-free regimens in 149'816 chronic hepatitis C treated Egyptian patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1296-1305	6.1	9
237	Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , <b>2018</b> , 38, 266-277	7.9	9
236	Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 422-431	3.1	9
235	LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e129-e130	13.4	9
234	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 609-618	4.7	9
233	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. <i>Journal of Leukocyte Biology</i> , <b>2015</b> , 98, 283-94	6.5	9
232	Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 1278-85	2.2	9
231	Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 994-1003	2.4	9
230	Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 80, 298-308	6.5	9
229	Analysis and function of delta-hepatitis virus-specific cellular immune responses. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 15-16	13.4	9
228	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 700-707	13.4	8
227	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , <b>2017</b> , 93, 46-52	14.5	8
226	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 133-140	1.6	8
225	Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset?. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 571166	8.4	8
224	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , <b>2020</b> , 40, 2164-2171	7.9	8
223	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 690-698	3.4	8
222	Risk factors and seroprevalence of hepatitis E evaluated in frozen-serum samples (2002-2003) of pregnant women compared with female blood donors in a Southern region of Brazil. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 1856-1862	19.7	8
221	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1033-1041	2.4	8



220	Successful clearance of hepatitis C virus with pegylated interferon $\beta$ -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1343-4	2.4	8
219	Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2007</b> , 19, 906-9	2.2	8
218	Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. <i>Frontiers in Public Health</i> , <b>2020</b> , 8, 424	6	8
217	Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4033-4042	4.1	8
216	Hepatitis E: An update on One Health and clinical medicine. <i>Liver International</i> , <b>2021</b> , 41, 1462-1473	7.9	8
215	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , <b>2016</b> , 80, 1-7	14.5	8
214	Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S159	13.4	8
213	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. <i>Liver International</i> , <b>2021</b> , 41, 295-299	7.9	8
212	Acute CMV-colitis in a patient with a history of ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2003</b> , 38, 119-22	2.4	8
211	Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. <i>Liver International</i> , <b>2017</b> , 37, 1468-1475	7.9	7
210	Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival. <i>Journal of Pathology: Clinical Research</i> , <b>2019</b> , 5, 164-176	5.3	7
209	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 974-986	3.4	7
208	Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. <i>Liver International</i> , <b>2020</b> , 40, 1225-1238	7.9	7
207	Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197544	3.7	7
206	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , <b>2014</b> , 60, 508-20	11.2	7
205	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 1020-32	3.4	7
204	Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2013</b> , 25, 1259-70	2.2	7
203	Treatment of chronic hepatitis B and the implications of viral resistance to therapy. <i>Expert Review of Anti-Infective Therapy</i> , <b>2008</b> , 6, 191-9	5.5	7



202	61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. <i>Journal of Hepatology</i> , <b>2008</b> , 48, S27-S28	13.4	7
201	Clinical Impact of Liver Biopsies in Liver Transplant Recipients. <i>Annals of Transplantation</i> , <b>2017</b> , 22, 108-114		7
200	Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. <i>Scientific Reports</i> , <b>2020</b> , 10, 16533	4.9	7
199	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , <b>2020</b> , 2, 100168	10.3	7
198	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1882-1887	4	7
197	Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1235-1241	8.9	7
196	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , <b>2017</b> , 141, 116-123	10.8	6
195	Development and performance of prototype serologic and molecular tests for hepatitis delta infection. <i>Scientific Reports</i> , <b>2018</b> , 8, 2095	4.9	6
194	Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , <b>2018</b> , 38, 2317-2328	7.9	6
193	Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S90	13.4	6
192	Exacerbation of hepatitis E virus infection during anti-TNF $\alpha$ treatment. <i>Joint Bone Spine</i> , <b>2017</b> , 84, 217-219		6
191	Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients. <i>Gastroenterology Insights</i> , <b>2012</b> , 4, e28	2.1	6
190	Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2013</b> , 10, 76-8	24.2	6
189	HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 631-9	3.4	6
188	Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 278-88	2.2	6
187	Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2007</b> , 19, 91-2	2.2	6
186	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
185	Autoimmune hepatitis induction can occur in the liver. <i>Liver International</i> , <b>2020</b> , 40, 377-381	7.9	6

184	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 72-82	11.2	6
183	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , <b>2016</b> , 65, 1015-23	19.2	6
182	Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment. <i>Medical Microbiology and Immunology</i> , <b>2016</b> , 205, 263-8	4	6
181	NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. <i>Liver Cancer</i> , <b>2019</b> , 8, 491-504	9.1	6
180	Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	6
179	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 534731	8.4	6
178	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2076	8.4	5
177	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , <b>2019</b> , 9, 14118	4.9	5
176	Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). <i>Substance Abuse: Research and Treatment</i> , <b>2019</b> , 13, 1178221819835847	1.6	5
175	P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S524-S525	13.4	5
174	Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. <i>Liver International</i> , <b>2018</b> , 38, 834-841	7.9	5
173	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , <b>2014</b> , 34, 1207-15	7.9	5
172	Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan?. <i>EBioMedicine</i> , <b>2015</b> , 2, 1564-5	8.8	5
171	Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 387-95	3.4	5
170	How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. <i>Viral Immunology</i> , <b>2014</b> , 27, 7-13	1.7	5
169	Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2008</b> , 46, 880-2	1.6	5
168	Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. <i>Hepatology Research</i> , <b>2005</b> , 31, 18-23	5.1	5
167	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0145409	3.7	5

166	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 194-195	6.1	5
165	Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. <i>Liver International</i> , <b>2021</b> , 41, 949-955	7.9	5
164	Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. <i>Hepato-Gastroenterology</i> , <b>1998</b> , 45, 1062-8		5
163	Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 166-8	3.1	5
162	Gilbert's syndrome and antiviral therapy of hepatitis C. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 246-50	3.1	5
161	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1057-64	4	4
160	Autophagy alleviates amiodarone-induced hepatotoxicity. <i>Archives of Toxicology</i> , <b>2020</b> , 94, 3527-3539	5.8	4
159	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. <i>Hepatology</i> , <b>2016</b> , 64, 2274-2276	11.2	4
158	Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 100-105	3.2	4
157	Treatment of hepatitis Delta. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, 237-239	2.2	4
156	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, S850-S851	0.7	4
155	Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, S862	0.7	4
154	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128069	3.7	4
153	Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, e169-70	3.4	4
152	1255 CHRONIC HEPATITIS E IN IMMUNOSUPPRESSED PATIENTS BEYOND LIVER- AND KIDNEY TRANSPLANTATION. <i>Journal of Hepatology</i> , <b>2011</b> , 54, S495	13.4	4
151	The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 221	13.4	4
150	Simultaneous mitral valve replacement and liver transplantation. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2011</b> , 59, 506-8	1.6	4
149	Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. <i>Vaccine</i> , <b>2009</b> , 27, 3099-108	4.1	4

148	Treatment of acute hepatitis C-how to explain the differences?. <i>Gastroenterology</i> , <b>2006</b> , 131, 682-3; author reply 683-4	13.3	4
147	Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1185-1193	2.2	4
146	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	4
145	Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1206-1218	3.4	4
144	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1851-1859	4	4
143	Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 546-7 <sup>6.1</sup>		4
142	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 1049-1056	2.2	4
141	Increase of $\beta$ -dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. <i>Oncotmunology</i> , <b>2021</b> , 10, 1874159	7.2	4
140	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy248	1	4
139	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 466-475	3.4	4
138	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199198	3.7	4
137	Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	4
136	Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 67-74	2.2	3
135	Current Management of HBV/HDV Coinfection and Future Perspectives. <i>Current Hepatology Reports</i> , <b>2015</b> , 14, 284-292	1	3
134	SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2019</b> , 51, 1962-1971	1.1	3
133	PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e113-e114	13.4	3
132	504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S207	13.4	3
131	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138503	3.7	3

130	Gender differences in patient receiving liver transplantation for viral hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2012</b> , 50, 760-5	1.6	3
129	Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 862-3	13.4	3
128	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134839	3.7	3
127	Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity. <i>Cell Stress</i> , <b>2018</b> , 2, 216-218	5.5	3
126	Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2020</b> , 103, 169-174	3.2	3
125	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , <b>2021</b> ,	19.2	3
124	Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13522	2.7	3
123	BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 736	9.8	3
122	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
121	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. <i>Hepatology Communications</i> , <b>2021</b> , 5, 97-111	6	3
120	Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	3
119	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 851-853	13.4	3
118	The Effect of Immunosuppression on Coagulation After Liver Transplantation. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1054-1065	4.5	2
117	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 187-92 <sup>2.2</sup>		2
116	HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , <b>2020</b> , 4, 983-997	6	2
115	Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 2797	4.9	2
114	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 920-929	3.4	2
113	The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , <b>2016</b> , 36, 473-6	7.9	2

112	A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S507	13.4	2
111	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e110	13.4	2
110	Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte. <i>Gastroenterologe</i> , <b>2015</b> , 10, 305-309	0.1	2
109	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145622	3.7	2
108	Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2014</b> , 52, 749-756	1.6	2
107	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , <b>2012</b> , 96, 51-8	10.8	2
106	382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX. <i>Journal of Hepatology</i> , <b>2011</b> , 54, S153	13.4	2
105	Is there a need for liver disease monitoring in HIV patients in Africa?. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 287-9	1.6	2
104	Of guinea pigs and men--an unusual case of jaundice. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2010</b> , 48, 33-7	1.6	2
103	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , <b>2011</b> , 87, 223-38	2	2
102	Hepatitis C virus living off the fat of the land. <i>Hepatology</i> , <b>2008</b> , 47, 343-5	11.2	2
101	Acute hepatitis C infection: Can immunology teach us the right way to treat?. <i>Current Hepatitis Reports</i> , <b>2004</b> , 3, 148-156		2
100	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 32, 223-229	2.2	2
99	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , <b>2020</b> , 40, 324-332	7.9	2
98	Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 341-351	1.6	2
97	Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 667253	6	2
96	Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
95	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , <b>2021</b> , 10,	7.9	2



94	Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T-Cell Responses in a Mouse Model. <i>Hepatology Communications</i> , <b>2021</b> , 5, 865-881	6	2
93	Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
92	Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S532-S533	13.4	2
91	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2021</b> ,	11.2	2
90	New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 831-839	4.6	2
89	Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial.. <i>Critical Care</i> , <b>2022</b> , 26, 134	10.8	2
88	The widespread rarity of HBsAg loss in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 190-192	18.8	1
87	Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. <i>Cancer Medicine</i> , <b>2019</b> , 8, 3793-3802	4.8	1
86	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , <b>2020</b> , 129, 104525	14.5	1
85	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1541-1543	5.1	1
84	UEG Week Vienna 2014 cutting edge symposium: Today's Science, Tomorrow's Medicine session features the immune system - a driving force in digestive health and disease. <i>United European Gastroenterology Journal</i> , <b>2014</b> , 2, 149-50	5.3	1
83	Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e175-8	3.4	1
82	Reply:. <i>Hepatology</i> , <b>2006</b> , 44, 511-512	11.2	1
81	Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2004</b> , 1, 24-5		1
80	A rare manifestation of Behçet's syndrome: immunological correlates and successful treatment of an esophageal ulcer. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 1385-91	4	1
79	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. <i>Current Hepatitis Reports</i> , <b>2003</b> , 2, 24-31		1
78	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.. <i>Virus Evolution</i> , <b>2022</b> , 8, veac007	3.7	1
77	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 841-846	1.6	1



76	Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. <i>Intensive Care Medicine Experimental</i> , <b>2021</b> , 9, 57	3.7	1
75	A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection.. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
74	Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0236528	3.7	1
73	Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 684424	8.4	1
72	Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , <b>2021</b> , 27, 887-899	4.5	1
71	Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. <i>Health Science Reports</i> , <b>2021</b> , 4, e290	2.2	1
70	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00371	4.2	1
69	Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. <i>Medicine (United States)</i> , <b>2021</b> , 100, e26571	1.8	1
68	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 229-231	13.4	1
67	Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study. <i>Intervirology</i> , <b>2016</b> , 59, 254-255	2.5	1
66	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224751	3.7	1
65	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230893	3.7	1
64	A transient early HBV-DNA increase during PEG-IFN $\alpha$ therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 410-419	3.4	1
63	T cell receptor repertoires within liver allografts are different to those in the peripheral blood. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1167-1175	13.4	1
62	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 296	3	1
61	Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 1376-1379	2.4	1
60	Hepatitis B virus: where are we and where are we going?. <i>Methods in Molecular Medicine</i> , <b>2004</b> , 96, 415-43		0
59	Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness.. <i>CardioVascular and Interventional Radiology</i> , <b>2022</b> , 45, 696	2.7	0

58	Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1582-1587	2.2	○
57	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , <b>2021</b> , 41, 1815-1823	7.9	○
56	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , <b>2021</b> , 41, 2046-2058	7.9	○
55	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab325	1	○
54	Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13553	2.7	○
53	Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 486-496	5.3	○
52	The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1474-1483	3.4	○
51	Impact of the COVID-19 pandemic on patients with liver cirrhosis-the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 954-960	1.6	○
50	Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered". <i>Journal of Hepatology</i> , <b>2021</b> , 75, 990-992	13.4	○
49	Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study.. <i>Critical Care</i> , <b>2022</b> , 26, 92	10.8	○
48	T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide. <i>Liver International</i> ,	7.9	○
47	Exacerbation d'infection par le virus de l'hépatite E au cours d'un traitement par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2017</b> , 84, 244-247	0.1	
46	Virale Infektionen bei Lebertransplantierten. <i>Gastroenterologe</i> , <b>2020</b> , 15, 227-234	0.1	
45	Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis-Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1231-1232	6.1	
44	E-xchange: Hepatitis E and the Risk of Plasma Products for Organ Transplant Recipients. <i>Transplantation</i> , <b>2018</b> , 102, 1209-1210	1.8	
43	Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 544-5	6.1	
42	EASL Recognition Awardee for 2014: Prof. Geoff-Dusheiko. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 466-8	13.4	
41	Reply to Letter to the Editor. <i>Current Opinion in Virology</i> , <b>2017</b> , 23, 131	7.5	

40	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , <b>2015</b> , 35, 2275-84	7.9
39	Immunopathogenesis of Hepatitis D <b>2014</b> , 231-241	
38	Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease. <i>Transplant Infectious Disease</i> , <b>2014</b> , 16, 958-67	2.7
37	Sind sich Jugendliche über die Gefahren einer Hepatitis-B-Virusinfektion als Geschlechtskrankheit bewusst?. <i>Monatsschrift Für Kinderheilkunde</i> , <b>2012</b> , 160, 477-483	0.2
36	Update on the Management of HBV-HDV Coinfection. <i>Current Hepatitis Reports</i> , <b>2012</b> , 11, 95-101	
35	O232: Hepatitis E: are serologic tests good enough and reliable?. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 12-14	1.4
34	Performance of HCV-Core Antigen Testing in Liver Transplanted Patients. <i>Transplantation</i> , <b>2012</b> , 94, 7	1.8
33	Treatment of Hepatitis E in Solid Organ Transplant Recipients. <i>Transplantation</i> , <b>2012</b> , 94, 543	1.8
32	Immune Responses in Acute and Chronic Hepatitis C <b>2007</b> , 193-208	
31	Hepatitis-A- und -E-Virus-Infektionen [Altes und Neues. <i>Krankenhaushygiene Up2date</i> , <b>2020</b> , 15, 375-389	0.2
30	Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany.. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2021</b> , 118, 797-798	2.5
29	Virale Hepatitiden [noch wie vor häufig und wichtig!. <i>Gastroenterologe</i> , <b>2021</b> , 16, 415-416	0.1
28	Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C [The TEPS Study. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , <b>2019</b> , 28, 15-26	1
27	Hepatitis D <b>2020</b> , 287-298	
26	In reply. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2015</b> , 112, 220	2.5
25	Hepatitis E <b>2016</b> , 69-73	
24	Virale Hepatitiden: Andere virale Infektionen <b>2016</b> , 75-79	
23	Hepatitis E <b>2016</b> , 69-73	

22	Hepatitis E seroprevalences in pregnant and non-pregnant women in a southern region of Brazil. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6
21	Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. <i>Blood</i> , <b>2016</b> , 128, 4898-4898	2.2
20	Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients receiving opioid substitution therapy in the German Hepatitis C-Registry. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6
19	Diversity of clinical presentation and virological characteristics of hepatitis delta: The hepatitis Delta International network (HDIN). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6
18	Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 mono-infection: Final results of the German HepNet Acute HCV IV Study. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6
17	Acute HCV <b>2012</b> , 13-20	
16	Antivirals in Acute Hepatitis C127-131	
15	Epidemiology and Natural History403-409	
14	Virale Hepatitiden: andere virale Infektionen <b>2014</b> , 1-6	
13	Hepatitis E <b>2014</b> , 1-6	
12	Reply to the Letter to the Editor: "Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma". <i>Liver Cancer</i> , <b>2020</b> , 9, 363-364	9.1
11	Diet-refractory NASH in an elderly woman. <i>Gut</i> , <b>2021</b> , 70, 1924-1945	19.2
10	HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 288	3
9	Virale Infektionen bei Lebertransplantierten. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , <b>2020</b> , 23, 240-245	0
8	Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1059-1060	13.4
7	Hepatitis D <b>2020</b> , 133-137	
6	Neue und aktuelle Therapieoptionen bei Hepatitis D. <i>Gastro-News</i> , <b>2021</b> , 8, 38-40	0
5	HCV [Eine Erkrankung auf dem Weg zur Eradikation?]. <i>Gastro-News</i> , <b>2018</b> , 5, 48-52	0

4	Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2007</b> , 53, 337-50	1.6
3	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3285	4.9
2	FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. <i>Biomedicines</i> , <b>2022</b> , 10, 1018	4.8
1	Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair.. <i>Scandinavian Journal of Gastroenterology</i> , <b>2022</b> , 1-8	2.4